Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | HTR3A | P46098 | 5/20 | 0.44 |
| ▸ | HTR3E | A5X5Y0 | 4/20 | 0.44 |
| ▸ | HTR3B | O95264 | 4/20 | 0.44 |
| ▸ | HTR3D | Q70Z44 | 4/20 | 0.44 |
| ▸ | HTR3C | Q8WXA8 | 4/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.43 |
| ▸ | GMNN | O75496 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12706575 | 0.89 | ALDH1A1 (0.57) | ALDH1A1GAAPOLBHTR3AL3MBTL1 | |
| SCHEMBL13008427 | 0.87 | ALDH1A1 (0.53) | ALDH1A1GAAPOLBL3MBTL1 | |
| SCHEMBL12728203 | 0.81 | ALDH1A1 (0.53) | ALDH1A1GAAPOLBL3MBTL1 | |
| SCHEMBL1594837 | 0.79 | ALDH1A1 (0.55) | ALDH1A1GAAPOLBL3MBTL1CYP2D6 | |
| SCHEMBL14423032 | 0.77 | ALDH1A1 (0.57) | ALDH1A1GAAPOLBL3MBTL1 | |
| SCHEMBL1594998 | 0.77 | ALDH1A1 (0.63) | ALDH1A1GAAPOLBL3MBTL1MEN1 | |
| SCHEMBL5211882 | 0.77 | ALDH1A1 (0.73) | ALDH1A1GAAPOLBL3MBTL1MEN1 | |
| SCHEMBL2058323 | 0.75 | ALDH1A1 (0.74) | ALDH1A1GAAPOLBL3MBTL1 | |
| SCHEMBL1574357 | 0.75 | ALDH1A1 (0.74) | ALDH1A1GAAPOLBL3MBTL1CYP2C19 | |
| SCHEMBL12706157 | 0.75 | ALDH1A1 (0.57) | ALDH1A1GAAPOLBL3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2465850-B1 | THERAPEUTIC COMPOUNDS | DART NEUROSCIENCE CAYMAN LTD (KY) | 2016-11-23 | — | — | EP | disclosed |
| US-8791137-B2 | Therapeutic compounds | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2014-07-29 | — | — | US | disclosed |
| US-8791137-B2 | Therapeutic compounds | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2014-07-29 | — | — | US | disclosed |
| US-8791137-B2 | Therapeutic compounds | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2014-07-29 | — | — | US | disclosed |
| EP-1989185-B1 | THERAPEUTIC COMPOUNDS | HELICON THERAPEUTICS INC (US) | 2013-05-22 | — | — | EP | disclosed |
| US-8399487-B2 | Pyrazole compounds and uses thereof | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2013-03-19 | — | — | US | disclosed |
| US-8399487-B2 | Pyrazole compounds and uses thereof | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2013-03-19 | — | — | US | disclosed |
| US-8399487-B2 | Pyrazole compounds and uses thereof | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2013-03-19 | — | — | US | disclosed |
| US-20110160248-A1 | PYRAZOLE COMPOUNDS AND USES THEREOF | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2011-06-30 | — | — | US | disclosed |
| US-20110160248-A1 | PYRAZOLE COMPOUNDS AND USES THEREOF | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2011-06-30 | — | — | US | disclosed |
| US-20110160248-A1 | PYRAZOLE COMPOUNDS AND USES THEREOF | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2011-06-30 | — | — | US | disclosed |
| US-7919626-B2 | Pyrazole compounds and uses thereof | HELICON THERAPEUTICS, INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-7919626-B2 | Pyrazole compounds and uses thereof | HELICON THERAPEUTICS, INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-20100317648-A1 | THERAPEUTIC COMPOUNDS | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2010-12-16 | — | — | US | disclosed |
| US-20100317648-A1 | THERAPEUTIC COMPOUNDS | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2010-12-16 | — | — | US | disclosed |
| US-20100317648-A1 | THERAPEUTIC COMPOUNDS | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2010-12-16 | — | — | US | disclosed |
| US-20070203154-A1 | Therapeutic Compounds | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2007-08-30 | — | — | US | disclosed |
| US-20070203154-A1 | Therapeutic Compounds | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2007-08-30 | — | — | US | disclosed |
| US-20070203154-A1 | Therapeutic Compounds | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317648-A1 | THERAPEUTIC COMPOUNDS | MAOB, MAOA, HTR1B | ALDH1A1 455/4885GAA 76/4885POLB 1119/4885 |
| US-20110160248-A1 | PYRAZOLE COMPOUNDS AND USES THEREOF | MAOB, MAOA, HTR1B | ALDH1A1 602/4885GAA 400/4885POLB 1529/4885 |
| US-20070203154-A1 | Therapeutic Compounds | MAOB, MAOA, HTR1B | ALDH1A1 455/4885GAA 76/4885POLB 1119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.